Status:

WITHDRAWN

Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)

Lead Sponsor:

Eurofarma Laboratorios S.A.

Conditions:

Cystitis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study is to assess if the efficacy of cephalosporin is similar to the efficacy of norfloxacin in the acute cystitis treatment.

Eligibility Criteria

Inclusion

  • Sign, initialize and date the informed consent form
  • Age ≥ 18 years
  • For urinary infection diagnosis, the following parameters must be considered in the urine I test:
  • Leukocyturia: ≥ 15,000 leukocytes
  • Epidermal cells: \< 20,000/mL
  • Presence of bacteriuria
  • Presence of nitrite (positive results)
  • To have a 2 points score (from 12 points) regarding the following symptoms of acute cystitis:
  • Dysuria
  • Urinary urgency
  • Frequent urination
  • Pain in the upper area of pubis
  • Each symptom must be scored according to the classification below. Total score may range from 0 to 12 points.
  • Severity Value Absent 0 Mild 1 Moderate 2 Severe 3

Exclusion

  • Research subjects that meet any of the criteria below will not be eligible for the study:
  • Asymptomatic urinary infection or infection in any organ
  • Documented incidence of UTI in the last year
  • Symptoms of pyelonephritis (cystitis symptoms plus fever, lower back pain or chills)
  • History of complicated urinary tract infection (congenital abnormalities, urinary tract distortion or obstruction, formation of calculus in the urinary tract)
  • Use of catheter in the urinary tract
  • Chronic renal or hepatic disease
  • Seizure-related diseases
  • Neurological deficits that interfere in the urinary flow and tract defense
  • Decompensated diabetes mellitus (fasting blood glucose ≥ 150 mg/dL);
  • Immunodepression:
  • Subjects with the human immunodeficiency virus (HIV)
  • Chronic use of corticosteroids in a dose ≥ 5 mg/day of prednisone for over 30 days
  • Any diseases related to immune dysfunction
  • Severe comorbidities (at the investigator's discretion)
  • History of allergy to penicillins, cephalosporines or quinolones
  • Subjects on medications such as antibiotics, amiodarone, antacids or sucralphate, tricyclic antidepressants, antipsychotics, cyclosporine, cisapride, didanosine, erythromycin, fembufeno, gliburide (a sulphonilurea), nitrofurantoin, probenecid, procainamide, quinidine, sotalol, teophylline, warfarin
  • Treatment due to UTI two weeks before entering study, or on antimicrobial treatment at least 3 times within the last 12 months
  • Use of phenazopyridine 7 days before entering the study
  • Hospitalization 30 days before study enrollment
  • Female research subjects that are pregnant, breastfeeding, or women with childbearing potential that deny to use at least two safe contraceptive methods during study
  • Participation in another clinical trial in the last 12 months

Key Trial Info

Start Date :

October 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01527019

Start Date

October 1 2012

Last Update

July 27 2015

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.